Director Bradley Thede purchased 835 shares of MYRG at $119.60, increasing holdings to 13,542 shares; stock now trading at $124.20 (-30.3% from 52-week high).
Director Favreau Bradley Thede purchased 835 shares at $119.60 on 2025-03-04, raising his post-transaction holdings to 13,542 shares. The purchase represents a 6.6% increase in his shareholding and occurs against a backdrop of significant recent price weakness: the stock is -12.2% over 30 days and -25.4% over 90 days, though it remains -30.3% below its 52-week high of $178.21. Notably, Thede's track record at this same ticker shows one prior buy on 2024-08-27 that generated a 90-day return of +60.2%, establishing a pattern of well-timed accumulation. The timing of this purchase, following material recent declines, is the primary signal for investor attention given the director's demonstrated ability to identify favorable entry points at this specific security.
MYRG Director Favreau buys 1,005 shares at $99.70; stock down 43.9% from 52-week high, now at $100.01
Director Favreau Bradley Thede purchased 1,005 shares at $99.70 on 2024-08-27, increasing his holdings by 8.6% to 12,707 shares post-transaction. The purchase occurs in a deteriorating price environment: the stock is -43.9% from its 52-week high of $178.21 and has declined 35.5% over the past 90 days, with current price at $100.01. This represents a rare insider purchase activity at a substantially depressed valuation relative to recent trading ranges, occurring while the company reports net losses of $-15.3M in the latest quarter despite 21.1% annual revenue growth. The confluence of asset accumulation by a director at a cyclical trough alongside negative quarterly earnings and steep drawdowns invites scrutiny of whether this reflects calculated entry or routine portfolio activity.
